α2C-Adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy

European Heart Journal

Volumn 27, Issue 4, 2006, Pages 454-459

  Regitz Zagrosek, Vera ^a,b   Hocher, Berthold ^b,c   Bettmann, Martin ^a   Brede, Marc ^d   Hadamek, Kerstin ^d   Gerstner, Carolin ^d   Lehmkuhl, Hans Brendan ^d   Hetzer, Roland ^a   Hein, Lutz ^d  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adrenoceptors; Chronic heart failure; Dilated cardiomyopathy

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ALPHA 2 ADRENERGIC RECEPTOR;

ADULT; ARTICLE; ASSISTED CIRCULATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GENOTYPE; HEART FAILURE; HEART GRAFT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN POLYMORPHISM; SURVIVAL; AGED; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HEART PACING; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS;

ADULT; AGED; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, ADRENERGIC, ALPHA-2; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 32144444496     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi659     Document Type: Article

References (20)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
2. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001;33:887-905.
3. MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
4. CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
5. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
6. Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 1989;69:864-989.
7. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999;402:181-184.
8. Hein L. Transgenic models of alpha 2-adrenergic receptor subtype function. Rev Physiol Biochem Pharmacol 2001;142:161-185.
9. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136.
10. Bunemann M, Bucheler MM, Philipp M, Lohse MJ, Hein L. Activation and deactivation kinetics of alpha 2A- and alpha 2C-adrenergic receptor-activated G protein-activated inwardly rectifying K+ channel currents. J Biol Chem 2001;276:47512-47517. Published online ahead of print October 8, 2001.
11. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol 2003;17:1640-1646. Published online ahead of print May 22, 2003.
12. O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, Foster E, Simpson PC. The alpha(1A/C)- and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest 2003;111:1783-1791.
13. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ, Hein L. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002;106:2491-2496.
14. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000;275:23059-23064.
15. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
16. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 999;96:7059-7064.
17. Engelhardt S, Boknik P, Keller U, Neumann J, Lohse MJ, Hein L. Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta1-adrenergic receptor. FASEB J 2001;15:2718-2720. Published online ahead of print October 15, 2001.
18. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999;99:649-654.
19. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-1142.
20. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, Sperfeld A, Glaser S. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 2000;101:2803-2809.